Compounding that statistic, prior studies indicate some trans people at high risk for HIV transmission are hesitant to take ...

Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Zimbabwe is preparing to place at least 46 500 people on a long-acting HIV prevention drug early next year marking the ...

The Trump administration's funding cuts to PEPFAR and USAID disrupted global HIV treatment and prevention, threatening progress made over decades. Lenacapavir's FDA approval as a long-acting ...

Bi-monthly HIV injection could transform care for breastfeeding mothers, improving suppression and cutting transmission.

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

Today, in Washington, D.C, Deputy Secretary of State Christopher Landau and Mozambican Minister of Foreign Affairs and Cooperation Maria Manuela dos ...

Empowering resilience in Mozambique under the America First Global Health Strategy Press Statement Thomas "Tommy" Pigott, Principal Deputy Spokesperson at the U ...

In today’s ACT Brief, we close out our McKinsey interview series with a look at how AI could transform clinical trials end to ...

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...